Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for GTC-Solid Tumor Profile (434 gene) TestHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for GTC-Solid Tumor Profile (434 gene) TestPR NewswireJanuary 7, 2020ReblogShareTweetShareIRVINE, Calif., Jan. 7, 2020 /PRNewswire/ -- Genomic Testing Cooperative, LCA announced that the Medicare Administrative Contractor Palmetto GBA (MolDx®) has established coverage for its solid tumor molecular profile.  The GTC-Solid Tumor Profile provides a comprehensive evaluation of the abnormalities in the entire coding sequence of 434 genes in various types of solid tumors.  This decision of covering solid tumors along with the previous coverage decision of two GTC hematology profiles allows GTC to offer comprehensive genomic profiling with next-generation sequencing (NGS) for patients with all types of cancer including a liquid biopsy for hematologic neoplasms.   Genomic Testing Cooperative (PRNewsfoto/Genomic Testing Cooperative, LCA)MoreLaboratories and hospitals that are members of the cooperative group as well as non-member medical professionals will have immediate access to these Medicare-covered tumor profiling tests. Dr. Maher Albitar, GTC Chief Executive Officer and Chief Medical Officer, stated "We are delighted that Palmetto GBA now covers our hematology and solid tumor profiles.  This full coverage along with our unique business model as a cooperative company will allow us to fulfill our mission in democratizing comprehensive molecular profiling of cancer and making it available and affordable for every patient with cancer."  Dr Albitar added "We believe that this coverage by Medicare will help other Co-op member laboratories and large oncology practice groups obtain coverage when they adapt or internalize our highly validated comprehensive molecular profiling tests.  This will not only improve patient care, but also reduce costs and deliver better standardized Precision Medicine."It is estimated that approximately 1.74 million Americans will be diagnosed with cancer every year and more than 14 million people are living with a diagnosis of cancer in the US. Cancer is currently the second leading cause of death in the US.   About Genomic Testing Cooperative, LCA Genomic Testing Cooperative (GTC) is a privately-owned molecular testing company located in Irvine, CA.  The company operates based on a cooperative (co-op) business model.  Members of the co-op hold type A shares with voting rights.  The company offers its patron members a full suite of comprehensive genomic profiling based mainly on next generation sequencing.  Molecular alterations are identified based on rigorous testing with the aid of specially developed algorithms to increase accuracy and efficiency.  The clinical relevance of the detected alterations is pulled from numerous databases using internally developed software.  Relevance of findings to diagnosis, prognosis, selecting therapy, and predicting outcome are reported to members.  The co-op model allows GTC to make the testing and information platform available to members at a lower cost because of a lower overhead. For more information, please visit https://genomictestingcooperative.com/.  Forward Looking Statements All of the statements, expectations and assumptions contained in this press release are forward-looking statements. Such forward-looking statements are based on the GTC management's current expectations and includes statements regarding the value of comprehensive genomic profiling, RNA profiling, DNA profiling, algorithms, therapy, the ability of testing to provide clinically useful information. All information in this press release is as of the date of the release, and GTC undertakes no duty to update this information unless required by law.Company contact: Jennifer VarcaGenomic Testing Cooperative.(949) 540-9421Jvarca@genomictestingcooperative.com CisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/genomic-testing-cooperative-gtc-receives-medicare-palmetto-gba-coverage-for-gtc-solid-tumor-profile-434-gene-test-300981968.htmlSOURCE Genomic Testing CooperativeReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextMedigap vs. Medicare AdvantageInvestopediaNKF Applauds Immunosuppressive Drug Coverage Legislation Introduced in the U.S. SenatePR NewswireGenetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye OnZacksJennie Garth Says Learning About Her Leaky Heart Valve Encouraged Her to 'Be More Educated' About Her HealthPeopleSanders' proposed funding plan may fall trillions shortFox BusinessBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoKorea Cases Top 2,000; Nigeria Confirms Infection: Virus UpdateBloomberg'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video